As of November 6, 2026, Assembly Biosciences, Inc. is a publicly traded company (Nasdaq: ASMB). The largest holder reporting an active stake on Schedule 13D is Gilead Sciences, Inc., at 25.1%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Commodore Capital (9.9%), RA Capital (9.5%), Janus Henderson (8.2%) (Schedule 13D/A, May 27, 2026).
Is this your company?
About to sign with, pay or invest in Assembly Biosciences, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Assembly Biosciences, Inc. a real, registered company?
- Assembly Biosciences, Inc. files with the SEC under CIK 1426800 (its SEC filings).
- Its shares are listed under the ticker ASMB on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in South San Francisco, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Assembly Biosciences, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Paradigm BioCapital Advisors LP (filed 2026-08-14).
Who are Assembly Biosciences, Inc.'s owners and officers?
Assembly Biosciences, Inc.: incorporated in Delaware; business address in South San Francisco, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Paradigm Biocapital Advisors LP | 7.8% |
| Schedule 13G/A, 2026-08-13 | Janus Henderson Group LTD. | 6.9% |
| Schedule 13G/A, 2026-08-04 | Farallon Capital Management, L.L.C. | 8.1% |
| Schedule 13D/A, 2026-05-27 | Gilead Sciences, Inc. | 25.1% |
| Schedule 13G, 2026-05-11 | Paradigm Biocapital Advisors LP | 5.4% |
| Schedule 13G/A, 2026-02-09 | Dapice Joshua J. | 7.8% |
| Schedule 13G, 2025-12-08 | Janus Henderson Group PLC | 8.2% |
| Schedule 13G, 2025-08-18 | Ra Capital Management, L.P. | 9.5% |
| Schedule 13G/A, 2025-08-18 | Alexander Schornstein | 3.49% |
| Schedule 13G, 2025-08-15 | Commodore Capital LP | 9.9% |
| Schedule 13G, 2025-08-15 | Dapice Joshua J. | 7.3% |
| Schedule 13G, 2025-08-12 | Alexander Schornstein | 4.68% |
Questions about who owns Assembly Biosciences, Inc.
Who owns Assembly Biosciences, Inc.?
On this page, 8 holders' latest ownership filings report 5% or more of Assembly Biosciences, Inc.: Gilead Sciences, Inc. (25.1%, Schedule 13D/A, filed 2026-05-27), Commodore Capital LP (9.9%, Schedule 13G, filed 2025-08-15), Ra Capital Management, L.P. (9.5%, Schedule 13G, filed 2025-08-18), Janus Henderson Group PLC (8.2%, Schedule 13G, filed 2025-12-08) and Farallon Capital Management, L.L.C. (8.1%, Schedule 13G/A, filed 2026-08-04); 3 more are listed above.
Who are the largest shareholders of Assembly Biosciences, Inc.?
By the share each holder's latest filing reports, the largest holders of Assembly Biosciences, Inc. on this page are Gilead Sciences, Inc. (25.1%), Commodore Capital LP (9.9%) and Ra Capital Management, L.P. (9.5%).
When did Gilead Sciences, Inc. buy into Assembly Biosciences, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Gilead Sciences, Inc. on this page is the Schedule 13D/A, filed 2026-05-27, reporting 25.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Assembly Biosciences, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Assembly Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Assembly Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Assembly Biosciences, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , Inc., a 10% owner: 4,977,089 shares (24.4% of shares outstanding) (Form 4, 2026-05-27).
- , a 10% owner: 728,113 shares (3.6% of shares outstanding) (Form 4, 2024-11-26).
- , the chief executive and president: 195,532 shares (0.96% of shares outstanding) (Form 4, 2026-11-03).
- , the chief scientific officer: 74,035 shares (0.36% of shares outstanding) (Form 4, 2026-11-03).
- , the chief manufacturing officer: 59,257 shares (0.29% of shares outstanding) (Form 4, 2026-11-03).
Shares outstanding: 20,360,596 as of 2026-08-07, from the company's latest SEC cover page.
How much has Assembly Biosciences, Inc. raised?
No fundraising or offering filing from Assembly Biosciences, Inc. is on file with us.
Keep reading
More on Assembly Biosciences, Inc. and the records around it.
Assembly Biosciences, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- GILEAD SCIENCES, INC. also filed stake reports on 5 other companies: Aspen Neuroscience, Inc. (Nov 2026), Arcus Biosciences, Inc. (Aug 2026), Arcellx, Inc. (Apr 2026)
- Farallon Capital Management, L.L.C. also filed stake reports on 18 other companies: EXELIXIS, INC. (Nov 2026), ENANTA PHARMACEUTICALS INC (Aug 2026), InflaRx N.V. (Aug 2026)
- Farallon Capital Partners, L.P. also filed stake reports on 19 other companies: BridgeBio Pharma, Inc. (May 2026), InflaRx N.V. (May 2026), Beta Bionics, Inc. (May 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/assembly-biosciences